In my article today I want to look at the devices part of the biotech world: here are 3 examples of some of the wonderful technology coming out of Australia and being taken to a global market.

In our “HOT” stock column, Michael Gable, Managing Director of Fairmont Equities, says that ResMed (RMD) RMD has come back to the long-term uptrend line and is starting to show some positive momen..

Companies bringing new copper production to the market over the next few years can expect to be looked upon very favourably by the market. Here are what I think are 3 outstanding prospects on the ASX.

In our “HOT” stock column, Michael Gable, Managing Director of Fairmont Equities, says that FMG is likely to begin the next phase of its uptrend

Here are charts investors need to look at and understand what they’re saying. These charts reinforce my views on investing this year.

Can there possibly be good buying in single-digit share prices? I’ve been trawling through the ASX-listed population looking for this kind of situation, and here are two single-digit share prices th..

In our “HOT” stock column, Michael Gable, Managing Director of Fairmont Equities, says that the chart for Orica (ORI) is reflecting the potential for further upside.

For our “HOT” stock, Raymond Chan, Head of Asian Desk at Morgans explains why he says to add Macquarie Bank (MQG) to your portfolio.

The fact of biotech investing is that the share prices are at the mercy of news flow from drug trial results, partnerships with bigger companies, regulatory interactions and a wide range of other even..

In our “HOT” stock column, Michael Gable, Managing Director of Fairmont Equities, says that based on its attractive valuation, there may be further upside in Altium (ALU) shares over the near term..